Pharmacokinetics, safety, and antihypertensive efficacy of losartan in combination with hydrochlorothiazide in hypertensive patients with renal impairment

Journal of Clinical Pharmacology

Volumn 43, Issue 6, 2003, Pages 591-603

  Dickson, Tania Z ^a   Zagrobelny, JoAnn ^a   Lin, Charles C ^a   Ritter, Michael A ^a   Snavely, Duane ^a   Ramjit, Denise ^a   Shahinfar, Shahnaz ^a   Lo, Man Wai ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Efficacy; Hydrochlorothiazide; Losartan; Pharmacokinetics; Renal impairment; Safety

Indexed keywords

HYDROCHLOROTHIAZIDE; LOSARTAN;

ABDOMINAL DISTENSION; ADULT; AGED; ANTIHYPERTENSIVE THERAPY; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; DEHYDRATION; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GASTROENTERITIS; GASTROINTESTINAL SYMPTOM; GOUT; HEADACHE; HEART PALPITATION; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; MENTAL DISEASE; METABOLIC DISORDER; MULTICENTER STUDY; NEUROLOGIC DISEASE; PHARMACODYNAMICS; SKIN APPENDAGE DISEASE; SKIN DISEASE; SOMNOLENCE; SWEATING; SYSTEMIC CIRCULATION; TACHYCARDIA; VERTIGO; VOMITING;

ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HALF-LIFE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; KIDNEY FAILURE; LOSARTAN; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; SAFETY;

EID: 0038243536     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270003253367     Document Type: Article

References (46)

1. Nelson E, Arcuri K, Ikeda L, Snavely D, Sweet C: Efficacy and safety of losartan in patients with essential hypertension. Am J Hypertens 1992;5:19A.
2. Toto R, Shultz P, Raij L, Mitchell H, Shaw W, Ramjit D, et al: Efficacy and tolerability of losartan in hypertensive patients with renal impairment. J Hypertens 1998;31:684-691.
3. Lukman LF, Berk LS, Tan LG, Tan SA: Losartan regresses left ventricular hypertrophy and improves ejection fraction in hypertensive diabetic patients. Chest 1996;110:109S.
4. Ragonesi PD, Belviso A, Tarsia C, Taddei MT: The effects of angiotensin II antagonist losartan on urinary albumin excretion in non insulin-dependent diabetes mellitus. Am J Hypertens 1998;11:47A.
5. de Pablos P, Martinez J, Aguilar J, Rodriguez F, Murado P, Macias A: Effects of losartan on blood pressure, microalbuminuria, insulin sensitivity and lipid profile in hypertensive type II diabetics with microalbuminuria. Atherosclerosis 1997;134:139.
6. Dujardin KS, Enriquez-Sarano M, Bailey KR, Seward JB, Tajik AJ: Effect of losartan on degree of mitral regurgitation quantified by echocardiography. Am J Cardiol 2001;87:570-576.
7. Stearns RA, Chakravarty PK, Chen R, Chiu SHL: Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Drug Metab Dispos 1995;23:207-215.
8. Yun C-H, Lee HS, Lee H, Rho JK, Jeong HG, Guengerich FP: Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Drug Metab Dispos 1995;23:285-289.
9. Lo MW, Goldberg MR, McCrea JB, Lu H, Furtek CI, Bjornsson TD: Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 1995;58:641-649.
10. Wong PV, Price WA, Chiu AT, et al: Non-peptide angiotensin II receptor antagonists: XI. Pharmacology of EXP3174, an active metabolite of DuP 753 - an orally active antihypertensive agent. J Pharmacol Exp Ther 1990;255:211-217.
11. Munafo A, Christen Y, Nussberger J, Shum LY, Borland RM, Lee RJ, et al: Drug concentration response relationships in normal volunteers after oral administration of losartan an angiotensin II receptor antagonist. Clin Pharmacol Ther 1992;51:513-521.
12. Sica DA, Lo MW, Shaw WC, Keane WF, Gehr TWB, Halstenson CE, et al: The pharmacokinetics of losartan in renal insufficiency. J Hypertens 1995;13(Suppl. 1):49S-52S.
13. Gansevoort RT, de Zeeuw D, Shahinfar S, Redfield A, de Jong PE: Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease. J Hypertens 1994;12(Suppl.):37S-42S.
14. de Zeeuw D, Gansevoort RT, Dullaart RPF, de Jong PE: Angiotensin II antagonism improves the lipoprotein profile in patients with nephrotic syndrome. J Hypertens 1995;13(Suppl. 1):53S-58S.
15. del Castillo D, Campistol JM, Guirado L, Capdevilla L, Martinez JG, Porfirio P, et al: Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients. Kidney Int 1998;54(Suppl. 68):135S-139S.
16. Fernandez-Andrade C, Russo D, Iversen B, Zucchelli P, Aranda P, Guerra L, et al: Comparison of losartan and amlodipine in renally impaired hypertensive patients. Kidney Int 1998;54(Suppl. 68):120S-124S.
17. Holdaas H, Hartmann A, Berg KJ, Lund K, Fauchald P: Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy. Nephrol Dial Transplant 1998;13:3096-3102.
18. Saracho R, Martin-Malo A, Martinez I, Aljama P, Montenegro J: Evaluation of losartan in hemodialysis (ELHE) study. Kidney Int 1998;54(Suppl. 68):125S-129S.
19. Fauvel JP, Velon S, Berra N, Pozet P, Madonna O, Zech P, et al: Effects of losartan on renal function in patients with essential hypertension. J Cardiovasc Pharmacol 1996;28:259-263.
20. Campistol JM, Inigo P, Jimenez W, Lario S, Clesca PH, Oppenheimer F, et al: Losartan decreases plasma levels of TGFβ in transplant patients with chronic allograft nephropathy. Kidney Int 1999;56:714-719.
21. Sica DA, Halstenson CE, Gehr TWB, Keane WF: Pharmacokinetics and blood pressure response of losartan in end-stage renal disease. Clin Pharmacokinet 2000;38:519-526.
22. Beermann B, Groschinsky-Grind M, Rosen A: Absorption, metabolism and excretion of hydrochlorothiazide. Clin Pharmacol Ther 1976;19:531-537.
23. Beermann B, Groschinsky-Grind M: Pharmacokinetics of hydrochlorothiazide in man. Eur J Clin Pharmacol 1977;12:297-303.
24. Niemeyer C, Hasenfuß G, Wais U, Knauf H, Schäfer-Korting M, Mutschler E: Pharmacokinetics of hydrochlorothiazide in relation to renal function. Eur J Clin Pharmacol 1983;24:661-665.
25. Bank N, Lief PD, Piczon O: Use of diuretics in treatment of hypertension secondary to renal disease. Arch Intern Med 1978;138:1524-1529.
26. Wollam GL, Tarazi RC, Bravo EL, Dustan HP: Diuretic potency of combined hydrochlorothiazide and furosemide therapy in patients with azotemia. Am J Med 1982;72:929-938.
27. Bennett WM, McDonald WJ, Kuehnel E, Hartnett MN, Porter GA: Do diuretics have antihypertensive properties independent of natriuresis? Clin Pharmacol Ther 1977;22:499-504.
28. Anderson J, Godfrey BE, Hill DM, Munro-Faure AD, Sheldon J: A comparison of the effects of hydrochlorothiazide and of furosemide in the treatment of hypertensive patients. Q J Med 1971;40:541-560.
29. Soffer BA, Wright J-TJ, Pratt JH, Wiens B, Goldberg AI, Sweet CS: Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 1995;26:112-117.
30. Naidoo DP, Sareli P, Marin F, Aroca-Martinez G, Maritz FJ, Jardim PCBV, et al: Increased efficacy and tolerability with losartan plus hydrochlorothiazide in patients with uncontrolled hypertension and therapy-related symptoms receiving two monotherapies. Adv Ther 1999;16:187-199.
31. Conlin PR, Elkins M, Liss C, Vrecenak AJ, Barr E, Edelman JM: A study of losartan, alone or with hydrochlorothiazide vs nifedipine GITS in elderly patients with diastolic hypertension. J Hum Hypertens 1998;12:693-699.
32. McCrea JB, Lo MW, Tomasko L, Lin CC, Hsieh JY-K, Capra NL, Goldberg MR: Absence of a pharmacokinetic interaction between losartan and hydrochlorothiazide. J Clin Pharmacol 1995;35:1200-1206.
33. Furtek CI, Lo MW: Simultaneous determination of a novel angiotensin II receptor blocking agent, losartan, and its metabolite in human plasma and urine by high-performance liquid chromatography. J Chromatogr 1992;573:295-301.
34. Hsieh JY, Lin C, Matuszewski BK, Dobrinska MR: Fully automated methods for the determination of hydrochlorothiazide in human plasma and urine. J Pharm Biomed Anal 1994;12:1555-1562.
35. Lam PC, Hung CR, Perrier DG: Estimation of variance for harmonic means half-lives. J Pharm Sci 1985;74:229-231.
36. Paterna S, Parrinello G, Scaglione R, et al: Effect of long-term losartan administration on renal haemodynamics and function in hypertensive patients. Cardiovasc Drugs Ther 2000;14:529-532.
37. Chan JC, Critchley JA, Tomlinson B, Chan TY, Cockram CS: Antihypertensive and anti-albuminuric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without non-insulin-dependent diabetes mellitus. Am J Nephrol 1997;17:72-80.
38. Laviades C, Varo N, Diez J: Transforming growth factor β in hypertensives with cardiorenal damage. Hypertension 2000;36:517-522.
39. Shand BI, Lynn KL: A comparative study of losartan and enalapril on erythropoiesis and renal function in hypertensive patients with renal parenchymal disease. Clin Nephrol 2000;54:427-428.
40. Schiller A, Ivan V, Gluhovschi G, Turcan M, Petrica L, Velciov S: Short-term therapy with AII receptor blocker losartan: cardiac and renal effects in patients with essential hypertension and hypertension of glomerular origin. Nephrol Dial Transplant 2001;14:63A.
41. Calvino J, Lens XM, Romero R, Sánchez-Guisande D: Long-term anti-proteinuric effect of losartan in renal transplant recipients treated for hypertension. Nephrol Dial Transplant 2000;15:82-86.
42. Navarro JF, Macia ML, Garcia J: Control of severe proteinuria with losartan after renal transplantation. Am J Nephrol 1998;18:261-262.
43. Madkour H, Gadallah M, Riveline B, Plante GE, Massry SG: Comparison between the effects of indapamide and hydrochlorothiazide on creatinine clearance in patients with impaired renal function and hypertension. Am J Nephrol 1995;15:251-255.
44. Beyer K-HJ, Ward TD, Vary JE, Gelarden RT, Knutson DW, Vesell ES: Contrasting effects of pyrazinoylguanidine and hydrochlorothiazide in patients with renal insufficiency. J Clin Pharmacol 1993;33:554-561.
45. Schiffl H, Schollmeyer P: Clinical efficacy and safety of long-term diuretic treatment in renal parenchymal hypertension. Int J Clin Pharmacol Ther Toxicol 1985;23:585-588.
46. Ruggenenti P, Brenner BM, Remuzzi G: Remission achieved in chronic nephropathy by a multidrug approach targeted at urinary protein excretion. Nephron 2001;88:254-259.